JP2016190804A - Iald産生促進剤 - Google Patents
Iald産生促進剤 Download PDFInfo
- Publication number
- JP2016190804A JP2016190804A JP2015071248A JP2015071248A JP2016190804A JP 2016190804 A JP2016190804 A JP 2016190804A JP 2015071248 A JP2015071248 A JP 2015071248A JP 2015071248 A JP2015071248 A JP 2015071248A JP 2016190804 A JP2016190804 A JP 2016190804A
- Authority
- JP
- Japan
- Prior art keywords
- iald
- bifidobacterium
- production
- production promoter
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 32
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims description 14
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 7
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 abstract description 5
- 102000015728 Mucins Human genes 0.000 abstract description 4
- 108010063954 Mucins Proteins 0.000 abstract description 4
- 229940051875 mucins Drugs 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 230000005694 interleukin-22 production Effects 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 102100030703 Interleukin-22 Human genes 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 108010074109 interleukin-22 Proteins 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012901 Milli-Q water Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 2
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 1
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186014 Bifidobacterium angulatum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
【解決手段】ビフィドバクテリウム属の菌、特にビフィドバクテリウム・ロンガムの菌を有効成分とすることで、安全にIALDの産生を促進し得る剤。
【選択図】なし
Description
すなわち、本発明は以下の構成からなる。
(1)ビフィドバクテリウム属の菌を有効成分とする、IALD産生促進剤。
(2)ビフィドバクテリウム属の菌がビフィドバクテリウム・ロンガムの菌である、上記(1)に記載のIALD産生促進剤。
(3)ビフィドバクテリウム属の菌がSBT−2928(FERM P−10657)である、上記(1)に記載のIALD産生促進剤。
1.1.菌体の準備
表1に示した乳酸菌11株及びビフィドバクテリウム属の菌12株を供試菌として使用した。乳酸菌はMRS液体培地にて、ビフィドバクテリウム属の菌はGAM液体培地にて37℃,16時間静置培養した。各菌体を遠心分離(1,912×g,4℃,10min)にて回収し、1mM MgSO4を含有する100mM リン酸カリウム緩衝液(pH7、以下、緩衝液と呼ぶ)を用いて3回洗浄した。
反応は休止菌体系にて実施した。表1に示したように、菌体懸濁液を供試菌によってO.D.600=3.7〜7.9に調整して、次のA、Bの2つの反応液組成にて37℃で18時間、反応を行った。
反応液組成A:20mM トリプトファン
反応液組成B:20mM トリプトファン and 20mM α−ケトグルタル酸
反応液は遠心分離後(9,100×g,4℃,10min)、上清を回収し、フィルター(0.22μm)にて不溶物を除去したものをHPLC分析サンプルとした。分析はAgilent社の1200シリーズを使用した。溶離液A(95% Milli−Q water,5% Acetonitrile(ACN),0.05% Trifluoroacetic acid(TFA))で平衡化したODSカラム(Hydrosphere C18 粒子径(μm)S−5,細孔径 4.6X250,品番 HS12S05−2546WT,メーカー YMC)に分析サンプルを10μlインジェクトし、流速1ml/minとして溶離液B(5% Milli−Q water,95% ACN,0.05% TFA)の濃度勾配(%B(time):10(0)→50(16)→50(16)→100(16.1)→100(20)→10(20.1)→10(26))により行った。カラムオーブンは40℃とした。分光光度計にてIALDの吸収波長の試験を行った結果、IALDの検出は300nmにおける吸収を利用した。ここで、合成活性(Synthesizing activity)を、反応により生成したIALD合成量(Concentration. ppm)を供試菌のO.D.600の値で割った値と定義する(式1)。
図1、図2より、α−ケトグルタル酸の有無に関わらず、ラクトバチルス属(Lactobacillus)と比較して、ビフィドバクテリウム属の菌(Bifidobacterium属)、特にビフィドバクテリウム・ロンガム(Bifidobacterium longum)のIALD産生能が優れていることが確認できた。また、その中でも特にSBT−2928(FERM P−10657)の効果が大きい事が確認できた。従って、これらのビフィドバクテリウム属の菌を有効成分として、IALD産生促進剤が提供できることが示された。
Claims (3)
- ビフィドバクテリウム属の菌を有効成分とする、IALD産生促進剤。
- ビフィドバクテリウム属の菌がビフィドバクテリウム・ロンガムの菌である、請求項1に記載のIALD産生促進剤。
- ビフィドバクテリウム属の菌がSBT−2928(FERM P−10657)である、請求項1または2に記載のIALD産生促進剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015071248A JP6666053B2 (ja) | 2015-03-31 | 2015-03-31 | Iald産生促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015071248A JP6666053B2 (ja) | 2015-03-31 | 2015-03-31 | Iald産生促進剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019101049A Division JP6802323B2 (ja) | 2019-05-30 | 2019-05-30 | Iald産生促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016190804A true JP2016190804A (ja) | 2016-11-10 |
JP6666053B2 JP6666053B2 (ja) | 2020-03-13 |
Family
ID=57245712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015071248A Active JP6666053B2 (ja) | 2015-03-31 | 2015-03-31 | Iald産生促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6666053B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020164492A (ja) * | 2019-03-29 | 2020-10-08 | 森永乳業株式会社 | インドール乳酸化合物の製造方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7080296B2 (ja) * | 2020-11-25 | 2022-06-03 | 雪印メグミルク株式会社 | Iald産生促進剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007020884A1 (ja) * | 2005-08-12 | 2007-02-22 | Meiji Dairies Corporation | β-ディフェンシンを介した感染予防効果を有するビフィズス菌または乳酸菌とそれを含有する食品・医薬品組成物 |
WO2012033151A1 (ja) * | 2010-09-09 | 2012-03-15 | 株式会社明治 | 炎症を抑制する組成物 |
JP2012526752A (ja) * | 2009-05-11 | 2012-11-01 | ネステク ソシエテ アノニム | ビフィドバクテリウム・ロンガムncc2705(cncmi−2618)及び免疫障害 |
-
2015
- 2015-03-31 JP JP2015071248A patent/JP6666053B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007020884A1 (ja) * | 2005-08-12 | 2007-02-22 | Meiji Dairies Corporation | β-ディフェンシンを介した感染予防効果を有するビフィズス菌または乳酸菌とそれを含有する食品・医薬品組成物 |
JP2012526752A (ja) * | 2009-05-11 | 2012-11-01 | ネステク ソシエテ アノニム | ビフィドバクテリウム・ロンガムncc2705(cncmi−2618)及び免疫障害 |
WO2012033151A1 (ja) * | 2010-09-09 | 2012-03-15 | 株式会社明治 | 炎症を抑制する組成物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020164492A (ja) * | 2019-03-29 | 2020-10-08 | 森永乳業株式会社 | インドール乳酸化合物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6666053B2 (ja) | 2020-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tian et al. | Bifidobacterium with the role of 5-hydroxytryptophan synthesis regulation alleviates the symptom of depression and related microbiota dysbiosis | |
MX2022003374A (es) | Cepas bacterianas, sus composiciones y su uso para el tratamiento de trastornos gastrointestinales. | |
López et al. | Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity | |
Al-Thubiani et al. | Identification and characterization of a novel antimicrobial peptide compound produced by Bacillus megaterium strain isolated from oral microflora | |
Das et al. | In vitro evaluation of anti-infective activity of a Lactobacillus plantarum strain against Salmonella enterica serovar Enteritidis | |
Donnarumma et al. | Lactobacillus crispatus L1: high cell density cultivation and exopolysaccharide structure characterization to highlight potentially beneficial effects against vaginal pathogens | |
MX2022003372A (es) | Cepas bacterianas, sus composiciones y su uso para el tratamiento de trastornos gastrointestinales. | |
MX2008006546A (es) | Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria. | |
Lee et al. | Novel probiotic mechanisms of the oral bacterium Streptococcus sp. A12 as explored with functional genomics | |
KR102248111B1 (ko) | 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체 | |
Fugaban et al. | Probiotic potential and safety assessment of bacteriocinogenic Enterococcus faecium strains with antibacterial activity against Listeria and vancomycin-resistant enterococci | |
EA201290527A1 (ru) | Способы выделения мононуклеарных клеток, которые включают субпопуляцию мезенхимальных клеток-предшественников, и сосудистых клеток, которые включают субпопуляцию эндотелиальных клеток-предшественников, из пуповинной ткани | |
Pingitore et al. | Characterization of salivaricin CRL 1328, a two-peptide bacteriocin produced by Lactobacillus salivarius CRL 1328 isolated from the human vagina | |
MX2022000369A (es) | Cepa bacteriana de bifidobacterium bifidum, las composiciones de la misma y usos relacionados. | |
Alexander et al. | Exploiting prophage-mediated lysis for biotherapeutic release by Lactobacillus reuteri | |
Wałecka et al. | Effect of osmotic stress and culture density on invasiveness of Listeria monocytogenes strains | |
JP6666053B2 (ja) | Iald産生促進剤 | |
Gaaloul et al. | Evaluation of Antimicrobial Activity and Safety Aspect of E nterococcus Italicus GGN 10 Strain Isolated from T unisian Bovine Raw Milk | |
Özçam et al. | A secondary metabolite drives intraspecies antagonism in a gut symbiont that is inhibited by cell-wall acetylation | |
JP2019137700A (ja) | Iald産生促進剤 | |
JP7080296B2 (ja) | Iald産生促進剤 | |
Chaalel et al. | Screening of plantaricin EF and JK in an Algerian Lactobacillus plantarum isolate | |
Khedr et al. | FolE gene expression for folic acid productivity from optimized and characterized probiotic Lactobacillus delbrueckii | |
MX2020013857A (es) | Bacterias bifidobacterium bifidum no viables y usos de las mismas. | |
Mulet et al. | Forkhead box protein O1 is linked to anti-inflammatory probiotic bacteria acting through nuclear factor-κB pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190530 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190821 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191211 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200219 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6666053 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |